Effect of 3-Alkylpyridine Marine Alkaloid Analogues in Leishmania Species Related to American Cutaneous Leishmaniasis

Chemical Biology and Drug Design

Volumn 80, Issue 5, 2012, Pages 745-751

  Machado, Patrícia A ^a   Hilário, Flaviane F ^b   Carvalho, Lidiane O ^a   Silveira, Mariana L T ^b   Alves, Rosemeire B ^b   Freitas, Rossimiriam P ^b   Coimbra, Elaine S ^a  

^a FEDERAL UNIVERSITY OF JUIZ DE FORA   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

3 alkylpyridine alkaloids; Leishmania; Marine alkaloids

Indexed keywords

3 ALKYLPYRIDINE ALKALOID; ALKALOID; ANTIPROTOZOAL AGENT; UNCLASSIFIED DRUG;

AMASTIGOTE; ANIMAL CELL; ANTIPROTOZOAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG SCREENING; DRUG SYNTHESIS; IC 50; LEISHMANIA; LEISHMANIA BRAZILIENSIS; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROMASTIGOTE; WILLIAMSON REACTION;

ALKALOIDS; ANIMALS; ANTIPROTOZOAL AGENTS; CELLS, CULTURED; HUMANS; INHIBITORY CONCENTRATION 50; LEISHMANIA; LEISHMANIASIS; MACROPHAGES; MICE; MICE, INBRED BALB C; NITRIC OXIDE; PYRIDINES;

LEISHMANIA AMAZONENSIS; LEISHMANIA BRAZILIENSIS;

EID: 84867231245     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/cbdd.12017     Document Type: Article

References (32)

1. World Health Organization (WHO). Leishmaniasis. Available at: http://www.who.int/leishmaniasis/en/ (accessed September 20, 2011).
2. Silveira F.T., Lainson R., De Castro Gomes C.M., Laurenti M.D., Corbett C.E. (2009) Immunopathogenic competences of Leishmania (V.) braziliensis and L. (L.) amazonensis in American cutaneous leishmaniasis. Parasite Immunol;31:423-431.
3. Amato V.S., Tuon F.F., Siqueira A.M., Nicodemo A.C., Neto V.A. (2007) Treatment of mucosal leishmaniasis in Latin America: systematic review. Am J Trop Med Hyg;77:266-274.
4. Larson E.E., Marsden P.D. (1987) The origin of espundia. Trans R Soc Trop Med Hyg;81:880-885.
5. Brasil (2010) Manual de Vigilância da Leishmaniose Tegumentar Americana, 3rd edn. Brasília (DF): Ministério da Saúde.
6. Silveira F.T., Lainson R., Corbett C.E. (2004) Clinical and immunopathological spectrum of American cutaneous leishmaniasis with special reference to the disease in Amazonian Brazil: a review. Mem Inst Oswaldo Cruz;99:239-251.
7. Oliveira L.F., Schubach A.O., Martins M.M., Passos S.L., Oliveira R.V., Marzochi M.C., Andrade C.A. (2011) Systematic review of the adverse effects of cutaneous leishmaniasis treatment in the New World. Acta Trop;118:87-96.
8. Barral A., Pedral-Sampaio D., Grimaldi Junior G., Momen H., McMahon-Pratt D., Jesus A.R., Badaró R., Barral-Netto M., Carvalho E.M., Jhonson W.D. (1991) Leishmaniasis in Bahia, Brazil: evidence that Leishmania amazonensis produces a wide spectrum of clinical disease. Am J Trop Med Hyg;44:536-546.
9. Tempone A.G., Martins de Oliveira C., Berlinck R.G. (2011) Current approaches to discover marine antileishmanial natural products. Planta Med;77:572-585.
10. Richard J.V., Werbovetz K.A. (2010) New antileishmanial candidates and lead compounds. Curr Opin Chem Biol;14:1-9.
11. Soto J., Arana B.A., Toledo J., Rizzo N., Vega J.C., Diaz A., Luz M., Gutierrez P., Arboleda M., Berman J.D., Junge K., Engel J., Sindermann H. (2004) Miltefosine for new world cutaneous leishmaniasis. Clin Infect Dis;38:1266-1272.
12. Avlonitis N., Lekka E., Detsi A., Koufaki M., Calogeropoulou T., Scoulica E., Siapi E., Kyrikou I., Mavromoustakos T., Tsotinis A., Golic Grdadolink S., Makriyannis A. (2003) Antileishmanial ring-substituted ether phospholipids. J Med Chem;46:755-767.
13. Cutignano A., Tramice A., De Caro S., Villani G., Cimino G., Fontana A. (2003) Biogenesis of 3-alkylpyridine alkaloids in the marine mollusc Haminoea Orbignyana. Angew Chem Int Ed;42: 2633-2636.
14. Mayer A.M.S., Rodríguez A.D., Berlinck R.G.S., Hamann M.T. (2009) Marine pharmacology in 2005-6: marine compounds with anthelmintic, antibacterial, anticoagulant, antifungal, anti-inflammatory, antimalarial, antiprotozoal, antituberculosis, and antiviral activities; affecting the cardiovascular, immune and nervous systems, and other miscellaneous mechanisms of action. Biochim Biophys Acta;1790:283-308.
15. Gupta L., Talwar A., Nishi Palne S., Gupta S., Chauhan P.M. (2007) Synthesis of marine alkaloid: 8, 9-dihydrocoscinamide B and its analogues as Novel class of antileishmanial agents. Bioorg Med Chem Lett;17:4075-4079.
16. Almeida A.M.P., Berlinck R.G.S., Hajdu E. (1997) Alcalóides alquilpiridínicos de esponjas marinhas. Quim Nova;20:170-185.
17. Dube A., Singh N., Saxena A., Lakshmi V. (2007) Antileishmanial potential of a marine sponge, Haliclona exigua against experimental visceral leishmaniasis. Parasitol Res;101:317-324.
18. Volk C.A., Kock M. (2004) Viscosaline: new 3-alkyl pyridinium alkaloid from the Arctic sponge Haliclona viscosa. Org Biomol Chem;2:1827-1830.
19. Kobayashi J., Murayama T., Ohizumi Y. (1989) Theonelladins A∼D, novel antineoplasic pyridine alkaloids from the okinawan marine sponge Theonella-swinhoei. Tetrahedron Lett;30:833.
20. Hilário F.F., de Paula R.C., Silveira M.L.T., Viana G.H.R., Alves R.B., Pereira J.R.C.S., Silva L.M., de Freitas R.P., de Pilla Varotti F. (2011) Synthesis and evaluation of antimalarial activity of oxygenated 3-alkylpyridine marine alkaloid analogues. Chem Biol Drug Des;78:477-482.
21. Mossman T. (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Meth;65:55-58.
22. Carmo A.M.L., Silva F.M.C., Machado P.A., Fontes A.P., Pavan F.R., Leite C.Q., Leite S.R., Coimbra E.S., Da Silva A.D. (2011) Synthesis of 4-aminoquinoline analogues and their platinum(II) complexes as new antileishmanial and antitubercular agents. Biomed Pharmacother;65:204-209.
23. de Carvalho G.S., Machado P.A., de Paula D.T., Coimbra E.S., da Silva A.D. (2010) Synthesis, cytotoxicity, and antileishmanial activity of N, N'-disubstituted ethylenediamine and imidazolidine derivatives. ScientificWorldJournal;10:1723-1730.
24. Green L.C., Wagner D.A., Glogwski J., Skipper P.L., Wishnok J.S., Tannenbaum S.R. (1982) Analysis of nitrate, nitrite, and nitrate in biological fluids. Anal Bioch;126:131-138.
25. Viana G.H., Santos I.C., Alves R.B., Gil L., Marazano C., Freitas-Gil R.P. (2005) Microwave-promoted synthesis of chiral pyridinium salts. Tetrahedron Lett;46:7773-7776.
26. Escobar P., Sangeeta M., Marques C., Croft S.L. (2002) Sensitivities of Leishmania species to hexadecylphosphocholine (miltefosine), ET-18-OCH3 (edelfosine) and amphotericin B. Acta Trop;81:151-157.
27. Coimbra E.S., Carvalhaes R., Grazul R.M., Machado P.A., De Souza M.V., Da Silva A.D. (2010) Synthesis, cytotoxicity and antileishmanial activity of some N-(2-(indol-3-yl)ethyl)-7-chloroquinolin-4-amines. Chem Biol Drug Des;75:628-631.
28. Vermeersch M., da Luz R.I., Tote K., Timmermans J.P., Cos P., Maes L. (2009) In vitro susceptibilities of Leishmania donovani promastigote and amastigote stages to antileishmanial reference drugs: practical relevance of stage-specific differences. Antimicrob Agents Chemother;53:3855-3859.
29. Sánchez-Moreno M., Gómez-Contreras F., Navarro P., Marín C., Ramírez-Macías I., Olmo F., Sanz A.M., Campayo L., Cano C., Yunta M.J.R. (2011) In vitro leishmanicidal activity of imidazole- or pyrazole-based benzo[g]phthalazine derivatives against Leishmania infantum and Leishmania braziliensis species. J Antimicrob Chemother;67:387-397.
30. Muylder G., Ang K.K.H., Chen S., Arkin M.R., Engel J.C., Mckerrow J.H. (2011) A Screen against Leishmania intracellular amastigotes: comparison to a promastigote screen and identification of a host cell-specific hit. PLoS Negl Trop Dis;5:e1253.
31. Evans T.G., Thai L., Granger D.L., Hibbs J.B. Jr (1993) Effect of in vivo inhibition of nitric oxide production in murine leishmaniasis. J Immunol;151:907-915.
32. Mayer A.M., Rodríguez A.D., Berlinck R.G., Fusetani N. (2011) Marine pharmacology in 2007-8: marine compounds with antibacterial, anticoagulant, antifungal, anti-inflammatory, antimalarial, antiprotozoal, antituberculosis, and antiviral activities; affecting the immune and nervous system, and other miscellaneous mechanisms of action. Comp Biochem Physiol C Toxicol Pharmacol;153:191-222.